Published in Proc Natl Acad Sci U S A on June 28, 2006
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol (2009) 3.86
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2011) 3.28
The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta (2007) 2.83
Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci U S A (2009) 2.68
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
CD95 promotes tumour growth. Nature (2010) 2.42
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One (2009) 2.30
Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest (2008) 2.26
Hepatocyte death: a clear and present danger. Physiol Rev (2010) 2.18
A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology (2012) 2.15
Apoptosis-induced compensatory proliferation. The Cell is dead. Long live the Cell! Trends Cell Biol (2008) 2.12
The role of JNK in the development of hepatocellular carcinoma. Genes Dev (2011) 2.07
Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A (2007) 1.89
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology (2011) 1.82
Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology (2009) 1.73
JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res (2012) 1.52
Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol (2012) 1.51
Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut (2010) 1.47
Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer (2009) 1.31
Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell (2012) 1.27
The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res (2012) 1.27
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancer. J Hepatol (2008) 1.25
Gadd45beta promotes hepatocyte survival during liver regeneration in mice by modulating JNK signaling. J Clin Invest (2008) 1.23
Reparative inflammation takes charge of tissue regeneration. Nature (2016) 1.21
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biol Chem (2009) 1.18
NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets (2008) 1.16
EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol (2014) 1.16
Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. Carcinogenesis (2011) 1.14
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer (2012) 1.13
A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. Proc Natl Acad Sci U S A (2012) 1.12
JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol (2014) 1.11
JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer (2009) 1.07
Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int (2012) 1.04
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML. J Exp Med (2014) 1.03
The JNKs differentially regulate RNA polymerase III transcription by coordinately modulating the expression of all TFIIIB subunits. Proc Natl Acad Sci U S A (2009) 1.02
The stress-regulated transcription factor CHOP promotes hepatic inflammatory gene expression, fibrosis, and oncogenesis. PLoS Genet (2013) 1.01
The 2 Faces of JNK Signaling in Cancer. Genes Cancer (2013) 1.00
Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest (2013) 0.97
HCV tumor promoting effect is dependent on host genetic background. PLoS One (2009) 0.95
Are hematopoietic stem cells involved in hepatocarcinogenesis? Hepatobiliary Surg Nutr (2014) 0.94
p62, Upregulated during Preneoplasia, Induces Hepatocellular Carcinogenesis by Maintaining Survival of Stressed HCC-Initiating Cells. Cancer Cell (2016) 0.93
Alcohol induces RNA polymerase III-dependent transcription through c-Jun by co-regulating TATA-binding protein (TBP) and Brf1 expression. J Biol Chem (2010) 0.93
Modulation of apoptotic signaling by the hepatitis B virus X protein. Viruses (2012) 0.93
Acquisition of an immunosuppressive protumorigenic macrophage phenotype depending on c-Jun phosphorylation. Proc Natl Acad Sci U S A (2014) 0.92
NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis. Gastroenterol Res Pract (2010) 0.91
The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev (2014) 0.91
Miz1 is a signal- and pathway-specific modulator or regulator (SMOR) that suppresses TNF-alpha-induced JNK1 activation. Proc Natl Acad Sci U S A (2009) 0.90
Therapeutic effect of c-Jun N-terminal kinase inhibition on pancreatic cancer. Cancer Sci (2013) 0.90
Cold-inducible RNA-binding protein promotes the development of liver cancer. Cancer Sci (2015) 0.89
TLRs, Alcohol, HCV, and Tumorigenesis. Gastroenterol Res Pract (2011) 0.88
p38α inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res (2012) 0.88
Site-specific ubiquitination is required for relieving the transcription factor Miz1-mediated suppression on TNF-α-induced JNK activation and inflammation. Proc Natl Acad Sci U S A (2011) 0.87
Role of innate immunity in the development of hepatocellular carcinoma. World J Gastroenterol (2013) 0.87
Molecular mechanisms underlying hepatocellular carcinoma. Viruses (2009) 0.87
Dihydromyricetin alleviates carbon tetrachloride-induced acute liver injury via JNK-dependent mechanism in mice. World J Gastroenterol (2015) 0.86
CYLD and HCC: when being too sensitive to your dirty neighbors results in self-destruction. Cancer Cell (2012) 0.86
TLRs, NF-κB, JNK, and Liver Regeneration. Gastroenterol Res Pract (2010) 0.86
A systems biology analysis of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics (2010) 0.85
Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res (2015) 0.85
Role of phosphorylated histone H3 serine 10 in DEN-induced deregulation of Pol III genes and cell proliferation and transformation. Carcinogenesis (2013) 0.85
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy. Semin Radiat Oncol (2013) 0.83
The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis. Carcinogenesis (2011) 0.83
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
Activation of JNK pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin. Hepatology (2017) 0.82
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol Biol Rev (2016) 0.81
Regulatory Roles of MAPK Phosphatases in Cancer. Immune Netw (2016) 0.81
Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases. Mediators Inflamm (2015) 0.81
Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells. Expert Rev Clin Immunol (2015) 0.81
Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3. Mol Endocrinol (2014) 0.80
JNK at the crossroad of obesity, insulin resistance, and cell stress response. Mol Metab (2016) 0.80
Structural and functional analysis of the natural JNK1 inhibitor quercetagetin. J Mol Biol (2012) 0.79
In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci (2015) 0.79
Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma. PLoS One (2013) 0.79
The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor? J Hepatol (2007) 0.79
Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. J Cancer Res Clin Oncol (2010) 0.79
Involvement of JNK in the embryonic development and organogenesis in zebrafish. Mar Biotechnol (NY) (2013) 0.79
Activation of c-Jun N-terminal kinase (JNK) during mitosis in retinal progenitor cells. PLoS One (2012) 0.79
JNK Signaling in the Control of the Tumor-Initiating Capacity Associated with Cancer Stem Cells. Genes Cancer (2013) 0.79
Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma. Mol Cancer (2010) 0.79
A New Paradigm to Mitigate Osteosarcoma by Regulation of MicroRNAs and Suppression of the NF-κB Signaling Cascade. Balsaenggwa Saengsig (2014) 0.79
Inflammation Mediated by JNK in Myeloid Cells Promotes the Development of Hepatitis and Hepatocellular Carcinoma. Cell Rep (2016) 0.78
The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract (2011) 0.78
Molecular Link between Liver Fibrosis and Hepatocellular Carcinoma. Liver Cancer (2013) 0.78
Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis. Am J Pathol (2011) 0.78
Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions. Sci Rep (2016) 0.78
Oppositional regulation of Noxa by JNK1 and JNK2 during apoptosis induced by proteasomal inhibitors. PLoS One (2013) 0.78
TAK1 binding protein 2 is essential for liver protection from stressors. PLoS One (2014) 0.77
Emerging role of Toll-like receptor 4 in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.77
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
Primary liver cancer: worldwide incidence and trends. Gastroenterology (2004) 11.21
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev (1993) 10.01
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (2003) 9.94
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem (1991) 7.22
Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature (2001) 5.71
Liver regeneration. J Hepatol (2000) 5.22
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
Inhibition of JNK activation through NF-kappaB target genes. Nature (2001) 5.03
Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature (1991) 4.74
Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A (1997) 4.33
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell (2003) 3.92
A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell (2003) 3.90
IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A (2003) 3.80
Inflammation and necrosis promote tumour growth. Nat Rev Immunol (2004) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Blocking IL-1 in systemic inflammation. J Exp Med (2005) 3.37
IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J (2003) 3.37
Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 3.28
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta (1997) 2.72
Transcriptional regulation of the Vascular Endothelial Growth Factor gene--a concert of activating factors. Cardiovasc Res (2005) 2.52
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol (1994) 2.26
N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol Ther (1996) 2.24
Activation of the JNK signaling pathway: breaking the brake on apoptosis. Bioessays (2003) 2.11
Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol (1990) 2.10
c-Jun N-terminal protein kinase 1 (JNK1), but not JNK2, is essential for tumor necrosis factor alpha-induced c-Jun kinase activation and apoptosis. Mol Cell Biol (2004) 1.93
c-Jun-N-terminal kinase drives cyclin D1 expression and proliferation during liver regeneration. Hepatology (2003) 1.87
High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-kappaB activation. Nat Med (2000) 1.82
Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease. Semin Liver Dis (1999) 1.55
Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol Biol Cell (1999) 1.42
Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B viruses. Mol Cell Biol (1993) 1.38
Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem Biophys Res Commun (1993) 1.38
Mechanisms of liver regeneration and their clinical implications. J Hepatobiliary Pancreat Surg (2005) 1.29
Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer. Toxicol Pathol (2005) 1.25
Liver tumour promotion by chemicals: models and mechanisms. Cancer Surv (1986) 1.25
Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem (1996) 1.24
MAGE-A4 interacts with the liver oncoprotein gankyrin and suppresses its tumorigenic activity. J Biol Chem (2003) 1.15
Induction of cyclin mRNA and cyclin-associated histone H1 kinase during liver regeneration. J Biol Chem (1992) 1.07
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene (2002) 1.06
Genetic profiling of human hepatocellular carcinoma. Semin Liver Dis (2005) 0.99
High, persistent hepatocellular proliferation and apoptosis precede hepatocarcinogenesis in growth hormone transgenic mice. Liver (1999) 0.94
The role of Ito cells in the biosynthesis of HGF-SF in the liver. EXS (1993) 0.87
Apoptosis and multistage carcinogenesis in rat liver. Mutat Res (1995) 0.86
Mechanisms of cell injury with hepatotoxic chemicals. Pharmacol Rev (1984) 0.82
Immunity, inflammation, and cancer. Cell (2010) 28.27
Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83
A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07
Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85
AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10
Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16
Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98
IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67
Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36
Inflammation and colon cancer. Gastroenterology (2010) 6.32
Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17
NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13
Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72
The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38
JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38
Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25
The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18
NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74
Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56
Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41
Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33
IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31
An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29
Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98
Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86
The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85
A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66
Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58
Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51
The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18
IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 2.89
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 2.74
Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70
A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64
Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56
Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52
Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A (2006) 2.49
Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res (2010) 2.48
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity (2010) 2.47
JNK1 is required for maintenance of neuronal microtubules and controls phosphorylation of microtubule-associated proteins. Dev Cell (2003) 2.45
Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell (2010) 2.43
The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett (2004) 2.41
p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell (2005) 2.38
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity (2006) 2.33
Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med (2004) 2.32
Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A (2010) 2.32
p63 induces key target genes required for epidermal morphogenesis. Proc Natl Acad Sci U S A (2007) 2.31
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol Cell (2003) 2.23
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature (2004) 2.21